Trial of MSC1936369B in Subjects With Solid Tumors
Status:
Completed
Trial end date:
2016-04-30
Target enrollment:
Participant gender:
Summary
This is a first in man trial with a primary objective being the determination of the Maximum
Tolerated dose (MTD) and the dose-limiting toxicity (DLT) in several regimens of MEK
inhibitor MSC1936369B administered orally once a day, in subjects with malignant solid tumors
to see how safe is treatment with MSC1936369B.